V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma-Reference-Cited by-同舟云学术

V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma

Published:2019-09-19 Issue:2 Volume:33 Page:303-311
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Mod Pathol

Author:

Muller Stephanie,Victoria Lai W.,Adusumilli Prasad S.^ORCID,Desmeules Patrice,Frosina Denise,Jungbluth Achim,Ni Ai,Eguchi Takashi,Travis William D.,Ladanyi Marc,Zauderer Marjorie G.^ORCID,Sauter Jennifer L.

Publisher

Springer Science and Business Media LLC

Subject

Pathology and Forensic Medicine

Link

http://www.nature.com/articles/s41379-019-0364-z.pdf

Reference41 articles.

1. Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017;18:623–30.

2. Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Do P, Bylicki O, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20:239–53.

3. Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, et al. Current and future management of malignant mesothelioma: a consensus report from the national cancer institute thoracic malignancy steering committee, international association for the study of lung cancer, and mesothelioma applied research foundation. J Thorac Oncol. 2018;13:1655–67.

4. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. NCCN Guidelines insights: malignant pleural mesothelioma, version 3. J Natl Compr Cancer Netw. 2016;14:825–36.

5. Maio M, Scherpereel A, Calabrò L, Aerts J, Cedres Perez S, Bearz A, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18:1261–73.

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lipid-based nanosystems: the next generation of cancer immune therapy;Journal of Hematology & Oncology;2024-07-19

2. VISTA: A Novel Checkpoint for Cancer Immunotherapy;Drug Discovery Today;2024-07

3. LRIG1 engages ligand VISTA and impairs tumor-specific CD8 ⁺ T cell responses;Science Immunology;2024-05-17

4. Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms;Cancer Immunology, Immunotherapy;2024-05-02

5. H-VISTA Immunohistochemistry Score Is Associated with Advanced Stages in Cutaneous and Ocular Melanoma;International Journal of Molecular Sciences;2024-04-14